PRNewsWire
01 Jun 2026, 03:09 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/hanmi-signs-licensing-deal-with-lilly-for-sonefpeglutide-lapsglp-2-analog-302786656.html
Read source
Search tags
Story key points
3 claims · impact-rated
Eli Lilly has acquired exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize Hanmi's sonefpeglutide. — Expanding a pipeline with a novel GLP-2 analog increases Lilly's therapeutic reach into intestinal growth and mucosal regeneration.
+0.60Hanmi will receive an upfront payment of $75 million and potential milestone payments totaling up to $1.185 billion. — This provides a significant immediate cash infusion and substantial future valuation upside for Hanmi Pharm.
+0.50Sonefpeglutide is currently undergoing a global Phase 2 clinical trial for short bowel syndrome (SBS). — Phase 2 status indicates the drug is past early safety checks but still carries significant clinical trial risk.
+0.30Ticker attribution
Model heads
Continue reading
6 related stories
The company signed a licensing deal providing an upfront payment of $75 million and potential milestones up to $1.185 billion.
The company has secured exclusive worldwide rights to a promising novel drug candidate, sonefpeglutide.
Impact vectors
9 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
5h ago
